Menu Close

Zometa Reduces Risk of Breast Cancer Recurrence in Patients Receiving Either Arimidex or Tamoxifen

The osteoporosis drug, Zometa, reduces risk of breast cancer recurrence in patients receiving either Arimidex or Tamoxifen, according to a study published in the June 4th The Lancet Oncology. Aromatase inhibitors such as Arimidex which are given to post-menopausal, hormone receptor positive women, are associated with an increased risk of osteoporosis. Bisphosphonates such as Zometa are often given to reduce this risk. They aren’t usually given to women receiving Tamoxifen as it isn’t associated with osteoporosis. However, according to the study, one additional benefit  is a significant increase in disease-free survival even two years after Zometa treatment was discontinued.

Link to Medline Health News Report

3 Comments

  1. Amy

    My daughter sent me this site last spring when I was diagnosed with Stage II breast cancer. It has been so helpful to me.
    I am now cancer free, as of Feb. 21.
    I have a little hint to help with stretching your arm and shoulder after surgery. Do jigsaw puzzles. Sit down and reach! My family made sure that I had a good supply of them!
    Thank you so much for the prayers listed on this site! God bless you!

  2. Linda

    My mom is a 5 survivor of breast and cervical cancer. She only received radiation. She currently takes Arimidex and has since her diagnosis. I’ve never heard mention of Zometa. Is it too late to begin this? Is this something I should bring to her Oncologists attention?

    Thank you.

    • helen

      Hi Linda, I don’t know the answer to that but it would be worth bringing up at the next oncologist’s appointment just to check.

Leave a Reply

Your email address will not be published. Required fields are marked *